Home Latest Articles
Latest Articles
  • Li LIU, Rui ZHANG, Xiaowei WANG
    World Clinical Drug. 2025, 46(9): 932-938.
    Objective

    To explore the application effect of Cangfu Daotan decoction in obese polycystic ovary syndrome(PCOS) with phlegm-damp stagnation syndrome and its influence on fat-related factors.

    Methods

    A randomized, double-blind, and superior trial design was adopted. A total of 103 obese patients with PCOS who were treated in our hospital from January 2022 to June 2023 were selected and randomly divided into the study group(n=52) and the control group(n=51). All patients were given conventional treatment, including improving metabolism and regulating endocrine, etc. The study group was additionally treated with Cangfu Daotan decoction. The clinical efficacy, leptin(LEP), adiponectin(APN), follicle stimulating hormone(FSH), and luteinizing hormone(LH), testosterone(T), blood lipid levels, insulin function and the occurrence of complications were compared between the two groups.

    Results

    After treatment, the total clinical effective rate of the study group was higher than that of the control group(88.46% vs. 72.55%), and the difference was significant(P<0.05). The APN levels in both groups were increased compared with those before(P<0.05), and the study group was higher than the control group(P<0.05). The levels of LEP, total cholesterol, triglycerides, low-density lipoprotein cholesterol, FSH, LH, T, homeostasis model assessment of insulin resistance, Vaspin, Apelin and traditional Chinese medicine syndrome score in both groups were decreased compared with those before(P<0.05), and those in the study group were lower than those in the control group(P<0.05). There was no significant difference in the occurrence of adverse reactions between the two groups(P>0.05).

    Conclusion

    Adding Cangfu Daotan decoction to the conventional treatment of obese PCOS patients with phlegm-damp stagnation syndrome can help improve the therapeutic effect, effectively improve the levels of fat-related factors, and bring certain benefits.

  • Guanghui LIU, Junfeng SUN
    World Clinical Drug. 2025, 46(9): 939-944.
    Objective

    To explore the efficacy of vonoprazan in patients with gastroesophageal reflux disease(GERD) and its influence on gastric mucosal barrier function.

    Methods

    A total of 120 GERD patients admitted to our hospital from January 2023 to December 2024 were selected and randomly divided into the observation group and the control group, with 60 cases in each group. The control group was treated with rabeprazole, while the observation group was treated with vonoprazan, both for 4 weeks. The clinical efficacy, Los Angeles classification score, GERD-Q, 24-hour pH resistance monitoring results, pepsinogen(PG) Ⅰ/Ⅱ, gastrin(GAS), motilin(MTL), tumor necrosis factor(TNF)-α, interleukin(IL)-6, and high-sensitivity C-reactive protein(hs-CRP), reflux conditions and adverse reactions were compared between the two groups.

    Results

    The total effective rate of the observation group was higher than that of the control group(91.67% vs. 76.67%, P<0.05). The Los Angeles classification and GRED-Q score of the observation group were both lower than those of the control group(P<0.05). The number of times the reflux time was ≥5 min, the longest reflux time, and the pH<4 time in the observation group were all less(shorter) than those in the control group(P<0.05) . The levels of PGⅠ/Ⅱ, GAS and MTL in the observation group were all higher than those in the control group(P<0.05), and TNF-α, IL-6 and hs-CRP were all lower(P<0.05).

    Conclusion

    Vonoprazan has a significant therapeutic effect on GERD and helps repair the gastric mucosal barrier function. Its mechanism might be related to potent acid suppression, anti-inflammation, etc.

  • Yuan YU, Dan CAO, Ting GUO, Quan ZHENG
    World Clinical Drug. 2025, 46(9): 945-951.
    Objective

    To explore the therapeutic effects and immune function of Heluo Shugan tablets as an adjuvant treatment in patients with hepatitis B virus decompensated cirrhosis.

    Methods

    A total of 80 patients with hepatitis B virus decompensated cirrhosis admitted to our hospital from January 2022 to June 2024 were selected and divided into the control group and the observation group, with 40 cases in each group. The control group received conventional treatment, while the observation group was treated in combination with Heluo Shugan tablets. Both groups received continuous treatment for 6 months. The clinical efficacy, hepatitis B virus deoxyribonucleic acid(HBV-DNA) load, alanine aminotransferase(ALT), aspartate aminotransferase(AST), total bilirubin(TBil), hyaluronic acid(HA), laminin(LN), procollagen type Ⅲ peptide(PC-Ⅲ), type Ⅳ collagen(Ⅳ-C), spleen thickness, inner diameter of portal vein, inner diameter of splenic vein, changes of cluster of differentiation antigen(CD)3+, CD4+, CD4+/CD8+, adverse reactions, complications and recompensatory conditions between the two groups were compared.

    Results

    After treatment, the total effective rates of Western medicine treatment(95.00% vs. 62.50%) and traditional Chinese medicine treatment(92.50% vs. 70.00%) in the observation group were both higher than those in the control group, and the differences were significant(P<0.05). Compared with the control group, the HBV-DNA load, ALT, AST, TBil, HA, LN, PC-Ⅲ, Ⅳ-C, spleen thickness, portal vein inner diameter and splenic vein inner diameter in the observation group were all lower, and CD3+, CD4+, CD4+/CD8+ were all higher, with significant differences(P<0.05). There was no statistically significant difference in the incidence of adverse reactions and complications between the two groups(P>0.05). The follow-up was conducted until April 2025. The recompensation rate of the observation group was higher than that of the control group(37.84% vs. 16.67%), and the difference was significant(P<0.05).

    Conclusion

    The use of Heluo Shugan tablets in patients with hepatitis B virus decompensated cirrhosis has received good application feedback and has relatively good safety.

  • Tao SHEN, Wei LI, Xiaotian XIE
    World Clinical Drug. 2025, 46(9): 952-957.
    Objective

    To investigate the therapeutic efficacy of doxycycline for macrolide-resistant Mycoplasma pneumoniae pneumonia(MRMP) in Chinese children after the corona virus disease 2019(COVID-19) pandemic.

    Methods

    Clinical data from MRMP studies in Chinese children over the past two years and the key parameters included clinical features(symptoms, signs, laboratory/imaging findings), drug efficacy and safety were collected through medical database searches. A systematic analysis evaluated the effectiveness and safety of doxycycline monotherapy for pediatric MRMP.

    Results

    A total of 200 pediatric MRMP cases were included. The overall effective rate of doxycycline was 88.5%(177/200), with fever reduction observed within 1.39 - 3.96 days after administration. No significant efficacy difference existed between severe Mycoplasma pneumoniae pneumonia group and non-severe Mycoplasma pneumoniae pneumonia group(83.1% vs. 91.1%, P>0.05). Adverse reactions to doxycycline occurred in only 5.5% of cases and were mild doxycycline significantly outperformed intravenous azithromycin in efficacy(92.6% vs. 67.6%, P<0.001), with comparable adverse reaction rates(7.4% vs. 9.5%, P>0.05).

    Conclusion

    Doxycycline has demonstrated significant clinical efficacy and good safety in pediatric MRMP. The infection rate of MRMP in children has continued to rise after COVID-19. Doxycycline provides a reliable intervention option for clinical use. Clinical application needs to enhance the ability to identify and diagnose MRMP in children at an early stage and continuously monitor possible long-term adverse drug reactions.

  • Yun ZHANG, Zhen FENG, Huiling LI, Tao WANG
    World Clinical Drug. 2025, 46(9): 958-965.
    Objective

    To comprehensively evaluate the efficacy, safety and economy of romosozumab in the treatment of osteoporosis(OP) based on rapid health technology assessment(rHTA), to provide a reference for clinical decision-making.

    Methods

    PubMed, Embase, Cochrane Liarbry, Wanfang, China National Knowledge Infrastructure, VIP database and rHTA-related websites were retrieved. Literature was independently screened according to the inclusion and exclusion criteria respectively, data extraction and quality evaluation were conducted, and descriptive analysis was performed.

    Results

    A total of 19 articles were included, including 14 systematic reviews or meta-analyses, 3 pharmacoeconomic studies, and 2 rHTA reports. In terms of effectiveness, romosozumab can reduce the risk of fractures in patients with OP, especially vertebral fractures. It can increase bone density, reduce the risk of falls, and improve trabecular bone analysis parameters(P<0.05). In terms of safety, there was no statistically significant difference in the occurrence of adverse events such as drug withdrawal due to adverse reactions, serious adverse reactions, cardiovascular risks, cancer and osteoarthritis in OP patients after treatment with romosozumab(P>0.05), but it did increase the reactions at the injection site. In terms of economy, romosozumab followed by alendronate sodium had a more cost-effectiveness advantage than alendronate sodium alone.

    Conclusion

    Romosozumab has good efficacy and safety in the treatment of OP and can be regarded as a medium and long-term treatment option.

  • Yanyan WANG, Miao WEI, Chunxia ZHANG, Jiaxiang ZHAO, Chao YAN, Yuan HE
    World Clinical Drug. 2025, 46(9): 966-971.
    Objective

    To explore the influence of early warning boundary value, response and hospital operation practice in practices for pediatric hand, foot and mouth disease(HFMD) based on control map method in the era of intelligent medicine.

    Methods

    The baseline database of children with hand, foot and mouth disease collected by the Municipal Center for Disease Control and Prevention from February 2023 to February 2024 was selected, and two prediction models were established based on the control map method, swinging the baseline data for 1 and 2 weeks, and recorded as models A and B, and the early warning boundary values of the two models were compared.

    Results

    From February 2023 to February 2024, a total of 12 719 cases of hand, foot and mouth disease were reported. Using the"epidemic" criterion to assess the prevalence and sporadic cases during this period, model A identified weeks 28—34 as the epidemic phase (6 weeks), while model B identified weeks 30—34 as the epidemic phase(4 weeks). Screening test calculations determined that model A's preferred warning threshold was P95, which is higher than model B's preferred threshold P9.

    Conclusion

    Model A and model B were constructed and evaluated based on the mobile average method. Model A was determined as the preferred model, and its P95 warning threshold could more accurately distinguish the prevalence and distribution of HFMD.

  • Junyi WANG, Haodong CHEN, Jiawei TANG, Songbai YANG, Shaoxin CHEN
    World Clinical Drug. 2025, 46(9): 972-977.

    With the increase of invasive fungal infections, the use of antifungal drug has become more frequently, and the emergence of fungal resistance has become an inevitable problem. Given the limited availability of existing antifungal drugs and their severe side effects, the United States Food and Drug Administration has approved a new antifungal drug, ibrexafungerp, which is a semi-synthetic chemical derivative of the natural product enfumafungin. It has broad-spectrum antibacterial activity, demonstrates strong antibacterial activity against Candida and Aspergillus, including those echinocandins- and azoles-resistant strains. It's currently used in the clinical treatment of vulvovaginal candidiasis. Ibrexafungerp has good oral bioavailability and tolerance, with few adverse reactions. It is a β-1, 3-glucan synthase inhibitor with a new structure and has a good prospect in the clinical treatment of invasive fungal infections. This article reviewed the research and development process, clinical research and drug interactions of ibrexafungerp.

  • Li'na CHEN, Hongling MA, Keran WANG, Lixin ZHANG, Guleng Siri
    World Clinical Drug. 2025, 46(9): 978-983.

    Non-alcoholic fatty liver disease(NAFLD) has become one of the most prevalent chronic liver diseases worldwide, with its incidence rising rapidly alongside the increasing prevalence of obesity and metabolic syndrome. At present, the treatment of NAFLD mainly relies on lifestyle intervention, but there is a lack of specific drugs. With in-depth research into the pathophysiological mechanisms of NAFLD, multiple drugs target metabolic disorders, inflammation, and fibrosis have become a hot topic. This article reviewed the latest advancements in NAFLD drug development, statistically analyzed global research trends and therapeutic hotspots, focused on introducing the clinical trial outcomes of metabolic modulators, anti-inflammatory or anti-fibrotic agents, and emerging targets, and discussed the future directions in this field.

  • Qian XING, Hui SUN, Wendi CHENG, Xiaochen PENG, Haiyin WANG
    World Clinical Drug. 2025, 46(9): 984-991.

    Since the implementation of pharmaceutical price disclosure in 2007, Australia has gradually implemented a mechanism for periodic adjustment of pharmaceutical prices, which has achieved remarkable results in controlling pharmaceutical prices, reducing healthcare expenditures, and ensuring that prices are open and reasonable. This paper analysed the background, adjustment mechanism and implementation process of the statutory price reduction and exemption system for PBS medicines, as well as the overall implementation effect. Finally, based on the practical experience of Australia, which provided a reference for optimizing the classification renewal rules of medical insurance drugs and building a long-term price management in China.

  • AIZEZIJIANG Aierken, Hongbin YI, Ningning WANG, Jiangtao ZHANG, HAISHAERJIANG Wushouer, Xiaodong GUAN, Luwen SHI, KAISAIER Abudukeremu
    World Clinical Drug. 2025, 46(9): 992-998.
    Objective

    To evaluate the impact of the pilot policy on the medical insurance payment standard for pilot drugs of a grade-A tertiary hospital in Xinjiang, and to provide empirical reference for the further optimization of medical insurance payment standard policies in Xinjiang.

    Methods

    Extracted the monthly data of pilot drug prices, usage amounts and usage quantities from the target hospital medicine management information system, checked the data integrity, and use the intermittent time series model to analyze the pilot drugs with high data integrity.

    Results

    A total of 5 pilot drugs were included. After the implementation of the pilot policy of medical insurance payment standard, the prices of Jinshuibao tablets, enteral nutrition emulsion and iron sucrose injection in the target hospitals showed a significant downward trend(P<0.05). The usage volume and expenditrue of Jinshuibao tablets immediately increased, while silymarin capsules and magnesium isoglycyrrhizinate injection showed a downward trend(P<0.05).

    Conclusion

    The prices and costs of most of the pilot drugs in the target hospitals have decreased significantly, and the usage amounts have also reduced, which helps to alleviate the financial burden of patients and save the medical insurance fund. Changes in the use of the pilot drugs vary and require further analysis in conjunction with other information. In addition, the pilot policy of medical insurance payment standard in Xinjiang still has a large lag.

News